<?xml version="1.0" encoding="UTF-8"?>
<p>Since the SARS-CoV outbreak in 2002â€“2003, numerous approaches have been used to develop therapeutic agents and vaccines for coronaviruses (
 <xref rid="biomedicines-08-00109-t002" ref-type="table">Table 2</xref>). The recent COVID-19 pandemic has further accelerated the efforts to find cure and protection. Typically, three general methods are employed for antiviral treatment of coronaviruses [
 <xref rid="B80-biomedicines-08-00109" ref-type="bibr">80</xref>]: (i) application of existing broad-spectrum antiviral drugs; (ii) screening of chemical libraries containing many existing compounds or databases; (iii) redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses. Other options include monoclonal antibodies and viral receptor blockers [
 <xref rid="B81-biomedicines-08-00109" ref-type="bibr">81</xref>]. Products developed as Chinese traditional medicines have also been suggested [
 <xref rid="B80-biomedicines-08-00109" ref-type="bibr">80</xref>]. In line with gene therapy applications, the design of various gene silencing approaches has been initiated based on RNA interference (RNAi) [
 <xref rid="B82-biomedicines-08-00109" ref-type="bibr">82</xref>]. In the context of vaccine development, a wide variety of immunization strategies have been initiated [
 <xref rid="B83-biomedicines-08-00109" ref-type="bibr">83</xref>].
</p>
